Jonsson Comprehensive Cancer Center: Lymphoma trials

The registry lists 24 Lymphoma studies with Jonsson Comprehensive Cancer Center as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 6Phase 2 12Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaCompletedNCT00182637Phase 2Results posted
• Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaTerminatedNCT02928510
• FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell LymphomaCompletedNCT01410630
• AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaStatus unknownNCT00324597Phase 1
• Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for CancerCompletedNCT00255749Phase 2
• Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00138164Phase 2
• Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00093769Phase 2
• Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive LymphomaTerminatedNCT00093704Phase 1
• Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00090909Phase 2
• Alemtuzumab in Treating Patients With Waldenstrom's MacroglobulinemiaWithdrawnNCT00081068Phase 2
• Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedNCT00070382Phase 3
• Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To ChemotherapyCompletedNCT00066508Phase 2
• Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's MacroglobulinemiaTerminatedNCT00060294Phase 1
• Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownNCT00042913Phase 2
• Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00040950Phase 1
• Carbendazim in Treating Patients With Advanced Solid Tumors or LymphomaStatus unknownNCT00023816Phase 1
• Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownNCT00022685Phase 3
• Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and NeutropeniaStatus unknownNCT00020865Phase 3
• Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00020800Phase 2
• Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a CatheterCompletedNCT00006083Phase 3
• Growth Factor to Prevent Oral Mucositis in Patients With Hematologic CancerCompletedNCT00004132Phase 2
• Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic CancerWithdrawnNCT00004114Phase 1
• Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell TransplantationCompletedNCT00003963Phase 2
• Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell TransplantationCompletedNCT00003143Phase 2